By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.
Ongoing education and proven outcomes need to aid this form of testing.
This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.
Vaccinations and mitigations for COVID-19 and other respiratory viruses have not been made a priority for young children. Let’s change this before the next big surge hits.
Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.
The recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.
Here is a review of using this therapy in this patient population.
The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.
Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.
Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.
This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.
Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?
Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.
This new program from the federal agency can be viewed as a useful starting point for the development and assessment tool for sepsis programs with more granularity required.
For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.
With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
This novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.
Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.
This flu season, the CDC reported at least 2.4 million flu illnesses, 23,000 hospitalizations, and 1,400 deaths from flu so far.
Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.
The evolution of the major variants, including the delta mutation.
Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
Although hospitalizations due to urinary tract infections have increased, there are some investigational antibiotics in clinical trials. Here is a review of some of these therapies in the pipeline.